Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview

Cabaletta Bio

11/08/2026 14:05

Cabaletta Bio, Inc. CABA.OQ CABA.O is expected to  show no change in quarterly revenue when it reports  results on August 13 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Cabaletta Bio, Inc. is for a loss of 37 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cabaletta Bio, Inc. is $14.00, about 400% above its last closing price of $2.80
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.40
-0.40
-0.39
Beat
2.9
Dec. 31 2026
-0.49
-0.46
-0.40
Beat
13.2
Sep. 30 2025
-0.48
-0.47
-0.44
Beat
6.8​
Jun. 30 2025
-0.67
-0.65
-0.73
Missed
-12.4
​​Mar. 31 2025
-0.64
-0.65
-0.71
Missed
-8.5
Dec. 31 2024
-0.63
-0.65
Missed
-3​
Sep. 30 2024
-0.59
-0.60
-0.62
Missed
-4
Jun. 30 2024
-0.56
-0.55
-0.56
Missed
-2.2
This summary was machine generated August 11 at 13:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)